Bimekizumab for treating moderate to severe plaque psoriasis

2.1 Bimekizumab (Bimzelx, UCB Pharma) has a marketing authorisation 'for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price of bimekizumab is £2,443 per 320 mg dose (two 160 mg prefilled syringes or prefilled pens; excluding VAT; price as quoted in company's submission).

2.4 The company has a commercial arrangement. This makes bimekizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.